Citigroup Inc Commence Coverage on Ovid Therapeutics Inc (OVID)

Citigroup Inc Commence Coverage on Ovid Therapeutics Inc (OVID)

Citigroup Inc started coverage on shares of Ovid Therapeutics Inc (NASDAQ:OVID) in a research report released on Tuesday morning. The brokerage issued a buy rating and a $21.00 target price on the stock.

Several other equities research analysts also recently commented on the company. William Blair assumed coverage on Ovid Therapeutics in a report on Tuesday. They issued an outperform rating on the stock. JMP Securities assumed coverage on Ovid Therapeutics in a report on Tuesday. They issued an outperform rating and a $26.00 target price on the stock. Finally, Cowen and Company assumed coverage on Ovid Therapeutics in a report on Tuesday. They issued an outperform rating on the stock.

Ovid Therapeutics (NASDAQ:OVID) opened at 11.68 on Tuesday. The company’s market capitalization is $247.06 million. The firm’s 50-day moving average is $13.81 and its 200-day moving average is $13.81. Ovid Therapeutics has a 52-week low of $11.46 and a 52-week high of $15.93.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:OVID”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment